New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
10:26 EDTEV, BHI, PSUN, MXIM, JNJ, LNG, TPH, SLB, PFE, LVS, FNP, BLK, UIS, TDG, SI, OHI, KIM, LLY, BP, ATI, BMRNOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Allegheny Technologies (ATI) downgraded to Hold from Buy at Deutsche Bank... BP (BP) downgraded to Neutral from Outperform at Exane BNP Paribas... BioMarin (BMRN) downgraded to Equal Weight from Overweight at Barclays... BlackRock (BLK) downgraded to Neutral from Buy at Goldman... Cheniere Energy (LNG) downgraded to Neutral from Buy at Citigroup... Eli Lilly (LLY) downgraded to Underweight from Equal Weight at Barclays... Fifth & Pacific (FNP) downgraded to Hold from Buy at Brean Capital... Johnson & Johnson (JNJ) downgraded to Equal Weight from Overweight at Barclays... Kimco Realty (KIM) downgraded to Sell from Neutral at UBS... Las Vegas Sands (LVS) downgraded to Market Perform from Outperform at FBR Capital... Maxim Integrated (MXIM) downgraded to Perform from Outperform at Oppenheimer... Omega Healthcare (OHI) downgraded to Sell from Neutral at UBS... Pacific Sunwear (PSUN) downgraded to Neutral from Buy at Janney Capital... Pfizer (PFE) downgraded to Market Perform from Outperform at Cowen... Siemens (SI) downgraded to Neutral from Buy at BofA/Merrill... Schlumberger (SLB) downgraded to Sector Perform from Outperform at Iberia... Baker Hughes (BHI) downgraded to Sector Perform from Outperform at Iberia... TransDigm (TDG) downgraded to Neutral from Buy at DA Davidson... TRI Pointe Homes (TPH) downgraded to Market Perform from Outperform at FBR Capital... Eaton Vance (EV) downgraded at Susquehanna... Unisys (UIS) downgraded to Neutral from Positive at Susquehanna.
News For ATI;BP;BMRN;BLK;LNG;LLY;FNP;JNJ;KIM;LVS;MXIM;OHI;PFE;PSUN;SI;SLB;BHI;TDG;TPH;EV;UIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
May 20, 2015
07:33 EDTJNJJ&J to file more than 10 new '$1B potenital' products by 2019
Subscribe for More Information
07:30 EDTJNJAchillion downgraded on valuation at JMP Securities
Subscribe for More Information
07:17 EDTBMRNBioMarin can rally over 25% on drisapersen approval, says Jefferies
Jefferies analyst Eun Yang sees greater than 25% upside in shares of BioMarin should the FDA approve drisapersen for Duchenne muscular dystrophy. After hosting an investor dinner with management, Yang says BioMarin's confidence in drisapersen approvability has increased. The analyst's model, which includes a price target for shares of $135 and a Buy rating, assumes 60% probability of approval for drisapersen. Shares of BioMarin closed yesterday down $1.03 to $124.99.
06:17 EDTJNJAchillion downgraded to Neutral from Buy at UBS
Subscribe for More Information
May 19, 2015
16:10 EDTJNJAchillion enters into collaboration for HCV with Janssen
Achillion (ACHN) announced that it has entered into a worldwide license and collaboration arrangement with Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), to develop and commercialize one or more of Achillion's lead hepatitis C virus, or HCV, assets which include ACH-3102, ACH-3422, and sovaprevir. Under the terms of the agreement, Achillion will grant Janssen an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillion's HCV assets. Achillion is eligible to receive a number of payments based upon achievement of specified development, regulatory and sales milestones. Achillion is also eligible to receive tiered royalty percentages between mid-teens and low-twenties based upon future worldwide sales. Janssen will be responsible for all of the development costs within the collaboration and all subsequent costs related to commercialization of the HCV assets. A key objective of the collaboration will be to develop a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of HCV. An initial regimen that will be explored will feature Achillion's ACH-3102, a second-generation NS5A inhibitor currently in Phase 2 clinical studies that has been granted Fast Track designation by the U.S. Food and Drug Administration, in combination with an NS3/4A HCV protease inhibitor plus an NS5B HCV polymerase inhibitor from the collaboration. Additionally, in an equity transaction separate to the exclusive license and collaboration arrangement, Johnson & Johnson Innovation JJDC, Inc. will invest $225M in Achillion and, in return, receive approximately 18.4M newly issued, unregistered shares of Achillion at a price of $12.25 per share. The transactions, including the equity sale, are subject to customary closing conditions, including termination or expiration of any applicable waiting periods under the Hart-Scott-Rodino Act. Transitional clinical development and technology transfer activities under the collaboration are expected to take place over the next several months.
15:00 EDTEVNotable companies reporting before tomorrow's open
Subscribe for More Information
08:23 EDTBHISiemens bond plan keeps it in running for Halliburton assets, Bloomberg says
Subscribe for More Information
07:31 EDTSLBUBS to hold a conference
Subscribe for More Information
07:04 EDTUISUnisys signs new contract with TravelSky
Subscribe for More Information
06:55 EDTPFEGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.
May 18, 2015
20:16 EDTPSUNUrban Outfitters down over 16% after disappointing Q1 results
Urban Oufitters (URBN) is down sharply after reporting first quarter earnings per share and revenue that missed analyst estimates. WHAT'S NEW: Urban Oufitters reported Q1 EPS of 25c on revenue of $739.01M, below consensus expectations of 30c and $758.25M, respectively. Urban Outfitters also reported Q1 comparable retail segment net sales up 4%, with Q1 retail segment net sales increasing 17% at Free People, 5% at Urban Outfitters, and 1% at the Anthropologie Group. Wholesale segment net sales rose 18%. WHAT'S NOTABLE: On its Q1 earnings conference call, Urban Outfitters announced that Urban Outfitters Group CEO Ted Marlow, who oversaw the direction of the namesake brand, would retire at the end of August. While Urban Outfitters did not provide guidance, Urban Outfitters Anthropologie Group CEO David McCreight commented on the Anthropologie brand, "We're expecting we could see Q2 shaping up like Q1 in terms of low single-digit comps. We could also see being in the low-mid-single digit comps. It's hard to tell at this point." ANALYST REACTION: Two analyst firms lowered their respective price targets on Urban Outfitters following the company's earnings report. Sterne Agee, which rates Urban Outfitters a Neutral, lowered its 12-month price target to $34 from $46, noting the company has had trouble getting both its Urban Outfitters and Anthropologie brands to perform at the same time. Cantor, which maintained its Buy rating, lowered its price target to $53 from $54, saying that Anthropologie sales disappointed, but noting that a "later catalog release appears to us to have pushed some sales at Anthropologie into May." PRICE ACTION: Urban Outfitters fell 16.4% to just over $34 in after-hours trading. PEERS: Other publicly traded companies in the space include Abercrombie & Fitch (ANF), American Eagle (AEO), Five Below (FIVE), Pacific Sunwear (PSUN), and Zumiez (ZUMZ).
11:10 EDTMXIMMaxim Integrated says order trends in industrial continue to improve
The company says industrial pick-up more U.S. and Europe based than Asian based.
11:04 EDTMXIMMaxim Integrated says will continue to see consolidation in the industry
Subscribe for More Information
11:00 EDTMXIMMaxim Integrated says goal for automotive gross margins is low 60s
Subscribe for More Information
10:01 EDTBP, LNG, LVSOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:25 EDTLNGOn The Fly: Pre-market Movers
Subscribe for More Information
08:12 EDTBPBP downgraded to Sell from Neutral at Goldman
Goldman downgraded BP to Sell based on limited upstream growth, a slowdown in asset disposals, and ongoing overhang from Macondo.
07:40 EDTLVSLas Vegas Sands downgraded to Neutral from Buy at Goldman
Subscribe for More Information
06:58 EDTPFEActavis CEO says chances of Pfizer offer are 'unlikely', Financial Times says
Actavis (ACT) CEO Brent Saunders said the chances of Pfizer (PFE) making an offer are "incredibly unlikely," reports the Financial Times. Saunders said he has heard the gossip that Actavis could become a takeover target for a larger group, but he spends "zero time thinking about it." Reference Link
06:58 EDTLNGCheniere Energy downgraded to Neutral from Buy at Goldman
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use